Gardner Lewis Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Gardner Lewis Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-131,142	Closed	-$15.2M	–	80
2023 Q3	$15.2M	Buy	+131,142	New	+$14.1M	5.23%	1
2023 Q2	–	Sell	-61,000	Closed	-$6.66M	–	94
2023 Q1	$6.66M	Buy	61,000 +38,500	+171%	+$4.26M	2.3%	19
2022 Q4	$2.56M	Buy	+22,500	New	+$1.87M	0.88%	33

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Gardner Lewis Asset Management's HZNP Position: Q4 2023 in Review

Gardner Lewis Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 131,142 shares — an estimated $15.2M sold.

Gardner Lewis Asset Management first reported a position in HZNP in Q4 2022 and held it in 3 quarters. The position peaked at $15.2M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Gardner Lewis Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Gardner Lewis Asset Management sold 131,142 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $15.2M.
Gardner Lewis Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 3 quarters.
Gardner Lewis Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $15.2M in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Gardner Lewis Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.